132 related articles for article (PubMed ID: 18280010)
1. [Therapeutic erythrocytapheresis: technical aspects and clinical applications].
Poullin P; Lefèvre P
Rev Med Interne; 2008 Apr; 29(4):290-6. PubMed ID: 18280010
[TBL] [Abstract][Full Text] [Related]
2. Survey on the usage of therapeutic erythrocytapheresis in transfusion services in Italy for the treatment of polycythemia vera, secondary erythrocytosis and hemochromatosis.
Iuliani O; Passeri C; Inghilleri G; Di Bartolomeo E; Abbruzzese L; Bianco I; Foddai ML; Natale GA; De Fusco G; D'Onofrio M; Fadda MG; Dominijanni A; Savignano C; Ostuni A
Transfus Apher Sci; 2023 Oct; 62(5):103752. PubMed ID: 37355441
[TBL] [Abstract][Full Text] [Related]
3. The efficiency of therapeutic erythrocytapheresis compared to phlebotomy: a mathematical tool for predicting response in hereditary hemochromatosis, polycythemia vera, and secondary erythrocytosis.
Evers D; Kerkhoffs JL; Van Egmond L; Schipperus MR; Wijermans PW
J Clin Apher; 2014 Jun; 29(3):133-8. PubMed ID: 24130064
[TBL] [Abstract][Full Text] [Related]
4. Clinical application of therapeutic erythrocytapheresis (TEA).
Valbonesi M; Bruni R
Transfus Sci; 2000 Jun; 22(3):183-94. PubMed ID: 10831921
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic erythrocytapheresis in the initial treatment of hereditary hemochromatosis.
Rehácek V; Bláha M; Jirousová H; Cernohorská J; Papousek P
Acta Medica (Hradec Kralove); 2012; 55(4):180-5. PubMed ID: 23631289
[TBL] [Abstract][Full Text] [Related]
6. Erythrocytapheresis versus phlebotomy in the maintenance treatment of HFE hemochromatosis patients: results from a randomized crossover trial.
Rombout-Sestrienkova E; Winkens B; Essers BA; Nieman FH; Noord PA; Janssen MC; van Deursen CT; Boonen A; Reuser-Kaasenbrood EP; Heeremans J; van Kraaij M; Masclee A; Koek GH
Transfusion; 2016 Jan; 56(1):261-70. PubMed ID: 26358375
[TBL] [Abstract][Full Text] [Related]
7. Pinch-off syndrome in patients with sickle cell disease receiving erythrocytapheresis.
Nuss R; Cole L; Le T; Orsini E; Harned R
Pediatr Blood Cancer; 2008 Feb; 50(2):354-6. PubMed ID: 17091481
[TBL] [Abstract][Full Text] [Related]
8. Erythrocytapheresis therapy to reduce iron overload in chronically transfused patients with sickle cell disease.
Kim HC; Dugan NP; Silber JH; Martin MB; Schwartz E; Ohene-Frempong K; Cohen AR
Blood; 1994 Feb; 83(4):1136-42. PubMed ID: 8111053
[TBL] [Abstract][Full Text] [Related]
9. The efficiency of therapeutic erythrocytapheresis compared to phlebotomy in relation to blood volume and delta-hematocrit: an evaluation in hereditary hemochromatosis polycythemia vera and secondary erythrocytosis.
Evers D; Kerkhoffs JL; Van Egmond L; Wijermans PW
Transfus Apher Sci; 2013 Apr; 48(2):187. PubMed ID: 23809828
[No Abstract] [Full Text] [Related]
10. [Blood rheologic disorders in patients with polycythemia vera and their correction by therapeutic erythrocytapheresis].
Likhovetskaia ZM; Prigozhina TA; Gorbunova NA; Kalinin NN; Petrov MM
Gematol Transfuziol; 1989 Nov; 34(11):33-6. PubMed ID: 2612862
[TBL] [Abstract][Full Text] [Related]
11. Erythrocytapheresis with recombinant human erythropoietin in hereditary hemochromatosis therapy: a new alternative.
Kohan A; Niborski R; Daruich J; Rey J; Bastos F; Amerise G; Herrera R; García M; Olivera W; Santarelli MT; Avalos JS; Findor J
Vox Sang; 2000; 79(1):40-5. PubMed ID: 10971213
[TBL] [Abstract][Full Text] [Related]
12. Successful long-term erythrocytapheresis therapy in a patient with symptomatic sickle-cell disease using an arterio-venous fistula.
Hartwig D; Schläger F; Bucsky P; Kirchner H; Schlenke P
Transfus Med; 2002 Feb; 12(1):75-7. PubMed ID: 11967141
[TBL] [Abstract][Full Text] [Related]
13. Effects of erythrocytapheresis transfusion on the viscoelasticity of sickle cell blood.
Thurston GB; Henderson NM; Jeng M
Clin Hemorheol Microcirc; 2004; 30(2):83-97. PubMed ID: 15004333
[TBL] [Abstract][Full Text] [Related]
14. [Advantages and difficulties of an erythrocytapheresis program for sickle-cell patients: a pediatric experience].
Filhon B; Dumesnil C; Holtermann C; Bastit D; Schneider P; Vannier JP
Arch Pediatr; 2012 Jun; 19(6):572-8. PubMed ID: 22542721
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of erythrocytapheresis in idiopathic hemochromatosis. Report of 14 cases.
Conte D; Mandelli C; Cesana M; Ferrini R; Marconi M; Bianchi A
Int J Artif Organs; 1989 Jan; 12(1):59-62. PubMed ID: 2925263
[TBL] [Abstract][Full Text] [Related]
16. [Comparison between phlebotomy and erythrocytapheresis of iron overload in patients with HFE gene mutations].
Fernández-Mosteirín N; Salvador-Osuna C; García-Erce JA; Orna E; Pérez-Lungmus G; Giralt M
Med Clin (Barc); 2006 Sep; 127(11):409-12. PubMed ID: 17020684
[TBL] [Abstract][Full Text] [Related]
17. Treatment of polycythemia vera by isovolemic large-volume erythrocytapheresis.
Kaboth U; Rumpf KW; Lipp T; Bigge J; Nauck M; Beyer JH; Seyde W; Kaboth W
Klin Wochenschr; 1990 Jan; 68(1):18-25. PubMed ID: 2308267
[TBL] [Abstract][Full Text] [Related]
18. Erythrocytapheresis in a Patient of Sickle Cell Disease Presenting in Crisis.
Raghuwanshi B
Mymensingh Med J; 2023 Oct; 32(4):1214-1216. PubMed ID: 37777924
[TBL] [Abstract][Full Text] [Related]
19. Current applications of therapeutic phlebotomy.
Assi TB; Baz E
Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s75-83. PubMed ID: 24120605
[No Abstract] [Full Text] [Related]
20. Red blood cell exchange in children with sickle cell disease.
Elenga N; Vantilcke V; Martin E; Cuadro E; Selles P; Basset T
Int J Hematol; 2022 Jan; 115(1):107-113. PubMed ID: 34550539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
